A Review of Voltammetric Methods for Determination of Dopamine Agonists

2020 ◽  
Vol 16 ◽  
Author(s):  
Fatma Ağin

Background: Dopamine agonists are useful drugs for the management of patients with Parkinson's disease in the early stages and in later stages of the disease. Parkinson's disease is a progressive neurodegenerative disease that primarily affects dopamine-producing nerve cells in the brain. They bind to dopamine receptors in nerve cells that regulate body movement and motor function. Electroanalytical methods are used in medicinal, clinical and pharmaceutical research. The voltammetry is one of the most commonly used electroanalytical methods. The aims of this review are to gather and discuss studies of voltammetric methods used in determination of dopamine agonists. Method: This review includes the use of various voltammetric methods for determination studies of dopamine agonists from pharmaceutical dosage forms and biological samples. These studies were examined in terms of used voltammetric method or methods, working electrode, buffer, pH and validation parameters. Results: Cabergoline, pramipexole, ropinirole have more studies, while bromocriptine and apomorphine have fewer studies in the literature. Differential pulse voltammetry and square wave voltammetry methods were the most applied methods for determination of dopamine agonist drugs from pharmaceuticals and biological samples. But, stripping, cyclic and lineer sweep voltammetry methods are less applied methods. In this studies, a lot of modified electrodes were developed and used to analyse of dopamine agonists. Conclusion: The voltammetric methods supply determination of therapeutic agents and/or their metabolites in clinical samples at extremely low concentrations without the necessity for the sample pre-treatment or time consuming extraction steps. Also the modified electrodes and validated voltammetric methods provide good stability, repeatability, reproducibility and high recovery for the analysis of the analyte.

2019 ◽  
Vol 15 (4) ◽  
pp. 423-442 ◽  
Author(s):  
Mona Habibi-Kool-Gheshlaghi ◽  
Farnoush Faridbod ◽  
Mahya Karami Mosammam ◽  
Mohammad Reza Ganjali

Background: Tricyclic psychotropic drugs are defined as a tricyclic rings of the dibenzazepine group with the presence of sulfur and nitrogen atoms. They have been prescribed for antidepressive therapy over the years. Due to their medical importance, many analytical methods have been developed for their monitoring. However, benefits of electrochemical techniques such as costeffectiveness, fast, easy operation and non-destructiveness make them appropriate analytical methods for drug assays. Electrochemical determinations of pharmaceuticals require suitable working electrodes. During years, many electrodes are modified by a variety of modifiers and several sensors were developed based on them. In this regard, nanomaterials, due to their remarkable properties, are one of the most important choices. Objective: Here, the application of electroanalytical methods in the determination of electroactive tricyclic psychotropic drugs will be reviewed and the nanomaterials which are used for improvements of the working electrodes will be considered.


RSC Advances ◽  
2016 ◽  
Vol 6 (110) ◽  
pp. 108635-108644 ◽  
Author(s):  
Xian-En Zhao ◽  
Yongrui He ◽  
Ping Yan ◽  
Na Wei ◽  
Renjun Wang ◽  
...  

In situ UA-DDLLME coupled with UHPLC-MS/MS has been developed for simultaneous determination of neurotransmitters and baicalein from Parkinson's disease rats.


2014 ◽  
Vol 5 (5) ◽  
pp. 357-358
Author(s):  
H. Kuusisto ◽  
P. Hujanen ◽  
T. Mattila ◽  
T. Luukkaala ◽  
T. Keränen

1991 ◽  
Vol 29 (2) ◽  
pp. 7-8

Bromocriptine, lysuride (formerly lisuride, Revanil – Roche) and pergolide (not yet marketed in the UK) are dopamine agonists developed for use in the treatment of patients with Parkinson’s disease. Combination of a dopamine agonist with levodopa plus a dopa-decarboxylase inhibitor (‘co-dieldopa’)* may have advantages at all stages of the disease. The aim of combined co-dieldopa + agonist treatment is to limit some of the problems with prolonged co-dieldopa use alone; especially fluctuations in motor disability.1 It is still not clear how the three agonists compare with each other for therapeutic efficacy, duration of action, and side effects, nor how they are best combined with co-dieldopa.


Sign in / Sign up

Export Citation Format

Share Document